相关实验视频

Updated: Jan 12, 2026

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

血原突变相关的血栓微血管病变和抗凝剂的作用:一个单一机构的病例系列

Shreya Agarwal¹, Nicola Pozzi², Senthil Sukumar³

¹Division of Hematology, Department of Pediatrics, University of California, San Francisco, California, USA.

Research and practice in thrombosis and haemostasis

|October 31, 2025

概括

血栓性微血管病变 (TMA) 患者的等离子素 (PLG) 基因突变与严重疾病和对补充物阻塞的反应不佳有关. 抗凝药可以防止这些PLG突变病例的复发.

科学领域:

血液学血液学血液学
遗传学遗传学是一个
分子生物学分子生物学

背景情况:

血栓性微血管病变 (TMA) 的发病因子尚未完全理解,特别是凝血途径突变的作用.
血原 (PLG) 基因突变与TMA有关,但关于它们对疾病发展和治疗结果的影响存在知识差距.

研究的目的:

描述PLG突变患者的独特临床和表型特征.
执行PLG变体的结构映射,以改善遗传发现的解释.

主要方法:

一个单一中心的回顾性研究分析了2011-2023年对TMA患者进行基因检测的数据.
对于具有PLG突变的患者,收集了人口统计,临床,结局,突变数据和复发信息.
用X射线结构数据来绘制PLG变体的结构映射.

主要成果:

在TMA队列中发现了6名具有PLG突变的个体.
第一次TMA事件发生时的中位数年龄为45.5岁,女性患者占主导地位 (83%).
一半的患者经历了复发的TMA,尽管补充物阻塞,但有一个病例复发;抗凝药在预防复发方面显示出希望.

结论:

与PLG突变相关的TMA可能对补充阻断反应不佳,这表明了替代或独立的致病途径.
需要进一步的研究来调查抗凝剂在预防PLG突变患者TMA复发中的有效性.

关键词:

这是一种抗凝血药物.补充补充封锁封锁在此之前,Eculizumab也曾被使用过.塑基因突变的发生血栓性微血管病变 - - 血栓性微血管病变

更多相关视频

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...